Related references
Note: Only part of the references are listed.Efficacy and safety of incretin therapy in type 2 diabetes - Systematic review and meta-analysis
Renee E. Amori et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes
Adrian Vella et al.
DIABETES (2007)
Effects of dipeptidyl peptidase IV on the satiety actions of peptide YY
S. Unniappan et al.
DIABETOLOGIA (2006)
The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans
JJ Meier et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2006)
The metabolite generated by dipeptidyl-peptidase 4 metabolism of glucagon-like peptide-1 has no influence on plasma glucose levels in patients with type 2 diabetes
M Zander et al.
DIABETOLOGIA (2006)
Emerging therapies mimicking the effects of amylin and glucagon-like peptide 1
MC Riddle et al.
DIABETES CARE (2006)
Insulin's direct effects on the liver dominate the control of hepatic glucose production
DS Edgerton et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice
XK Ding et al.
HEPATOLOGY (2006)
Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy
LA Nikolaidis et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2005)
Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage
C Knauf et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
Improved meal-related β-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year
B Ahrén et al.
DIABETES CARE (2005)
Incretins, insulin secretion and Type 2 diabetes mellitus
T Vilsboll et al.
DIABETOLOGIA (2004)
Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes
B Ahrén et al.
DIABETES CARE (2004)
Insulin-independent effects of GLP-1 on canine liver glucose metabolism: duration of infusion and involvement of hepatoportal region
D Dardevet et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2004)
The major glucagon-like peptide-1 metabolite, GLP-1-(9-36)-amide, does not affect glucose or insulin levels in mice
B Rolin et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2004)
Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets
L Farilla et al.
ENDOCRINOLOGY (2003)
Effects of 3 months of continuous subcutaneous administration of glucagon-like peptide 1 in elderly patients with type 2 diabetes
GS Meneilly et al.
DIABETES CARE (2003)
Effects of GLP-1-(7-36)NH2, GLP-1-(7-37), and GLP-1-(9-36)NH2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans
TP Vahl et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
Glucagon-like peptide-1 augments insulin-mediated glucose uptake in the obese state
JM Egan et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2002)
GLP-1-(9-36) amide reduces blood glucose in anesthetized pigs by a mechanism that does not involve insulin secretion
CF Deacon et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2002)
Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes:: a parallel-group study
M Zander et al.
LANCET (2002)
Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier
AJ Kastin et al.
JOURNAL OF MOLECULAR NEUROSCIENCE (2002)
Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor
R Burcelin et al.
DIABETES (2001)
Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats
R Perfetti et al.
ENDOCRINOLOGY (2000)
Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas
DA Stoffers et al.
DIABETES (2000)
Share Paper
